Compare MGTX & EMBC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | MGTX | EMBC |
|---|---|---|
| Founded | 2015 | 1924 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 665.7M | 719.7M |
| IPO Year | N/A | N/A |
| Metric | MGTX | EMBC |
|---|---|---|
| Price | $8.20 | $12.08 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 6 | 2 |
| Target Price | ★ $23.83 | $18.50 |
| AVG Volume (30 Days) | 620.5K | ★ 859.3K |
| Earning Date | 11-13-2025 | 02-05-2026 |
| Dividend Yield | N/A | ★ 4.97% |
| EPS Growth | N/A | ★ 20.90 |
| EPS | N/A | ★ 1.62 |
| Revenue | $27,417,000.00 | ★ $1,080,400,000.00 |
| Revenue This Year | N/A | $2.18 |
| Revenue Next Year | $619.95 | $0.09 |
| P/E Ratio | ★ N/A | $7.46 |
| Revenue Growth | ★ 96.83 | N/A |
| 52 Week Low | $4.55 | $9.20 |
| 52 Week High | $9.73 | $21.23 |
| Indicator | MGTX | EMBC |
|---|---|---|
| Relative Strength Index (RSI) | 51.70 | 45.39 |
| Support Level | $7.84 | $11.64 |
| Resistance Level | $8.53 | $12.30 |
| Average True Range (ATR) | 0.55 | 0.45 |
| MACD | -0.03 | 0.10 |
| Stochastic Oscillator | 35.84 | 79.06 |
MeiraGTx Holdings PLC is a clinical-stage gene therapy company. It focuses on the eye, salivary gland, and central nervous system disorders. The company's pipeline products include AAV-CNGB3, AAV-CNGA3 and AAV-RPGR, and others. Geographically, it operates in the United States, the United Kingdom, and European Union.
Embecta Corp is a medical device company focused on providing solutions to improve the health and well-being of people living with diabetes. It has a broad portfolio of marketed products, including various pen needles, syringes, and safety devices, which are complemented by a proprietary digital application designed to assist people with managing their diabetes. The company predominantly sells products to wholesalers and distributors that sell to retail and institutional channels who in turn sell to patients or use the products to deliver insulin injections to patients. It also provides contract manufacturing services. Geographically, the company derives a majority of its revenue from the United States.